Welcome to our dedicated page for Lichen International SEC filings (Ticker: LICN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Lichen China Limited (Lichen International Limited) (Nasdaq: LICN) provides access to the company’s regulatory disclosures as a foreign private issuer. Lichen files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934, offering detailed information on its financial and taxation solution services, education support services, and software and maintenance services in China.
Through its Form 6-K filings, Lichen furnishes materials such as management’s discussion and analysis of financial condition and results of operations, unaudited interim consolidated financial statements, and transaction-related disclosures. For example, the company has filed 6-Ks describing private placements of Class A ordinary shares, including the number of shares issued, purchase prices, and exemptions from registration relied upon. These filings are incorporated by reference into the company’s registration statements on Form S-8 and Form F-3, as noted in the reports.
Investors can also review filings that document equity and compensation arrangements, such as the Form 6-K reporting the approval and adoption of the Lichen International Limited 2025 Equity Incentive Plan, which is attached as an exhibit. Other filings describe agreements such as a debt settlement and mutual release agreement under which the company issued Class B ordinary shares to settle accrued but unpaid salary, providing insight into related-party transactions and capital structure.
Because LICN is listed on the Nasdaq Capital Market, its filings may also reference capital-raising activities and shelf registration statements, including a Form F-3 used for registered direct offerings of Class A ordinary shares or pre-funded warrants. While insider transaction reports on Form 4 are generally filed by insiders rather than the company, this page can be used alongside EDGAR data to track ownership and compensation-related information.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain key points from lengthy documents such as MD&A sections and financial statements. Real-time updates from EDGAR help users quickly locate new 6-Ks, registration-related disclosures, and equity plan documents, while AI-generated highlights aim to make complex regulatory language more accessible for readers analyzing LICN’s filings.
Lichen International Limited reports that shareholders approved all six proposals at an extraordinary general meeting held on December 30, 2025. Holders representing 15,970,739 voting power, or 92.23% of eligible votes as of November 21, 2025, were present in person or by proxy. Shareholders approved a major increase in authorised share capital from US$1,000,000 divided into 100,000,000 Series A and 25,000,000 Series B ordinary shares to US$200,000,000 divided into 20,000,000,000 Series A and 5,000,000,000 Series B ordinary shares. They also approved a future share consolidation at a ratio between one-for-20 and one-for-200, with the exact ratio and effective date to be set by the board within eighteen months and fractional shares rounded up. The meeting adopted extensive amendments to the memorandum and articles of association, including making annual general meetings optional, updating quorum rules tied to listed status, and replacing the governing documents with amended and restated versions.
Lichen International Limited has filed a Form F-3 shelf registration to offer up to $500,000,000 of Class A ordinary shares, share purchase contracts and units, warrants, debt securities, rights and units in one or more future offerings. The company’s Class A ordinary shares trade on Nasdaq under the symbol LICN, with a public float of 16,215,274 Class A shares held by non‑affiliates as of this prospectus.
Lichen is a Cayman Islands holding company whose operations are conducted through PRC subsidiaries providing financial and taxation solutions, education support, and software services, without a VIE structure. The filing highlights significant PRC legal, regulatory, cash‑transfer and HFCAA-related risks that could affect the value or tradability of its securities. Recent developments include a strategic shift toward IPO advisory and external equity investments, a $18,600,000 private placement of 15,500,000 Class A shares at $1.20 per share, and adoption of a 2025 equity incentive plan for up to 2,500,000 Class A shares.
Lichen International Limited filed a Form S-8 to register 2,500,000 Class A ordinary shares, par value US$0.008 per share, for issuance under its 2025 Equity Incentive Plan.
The registration also includes, pursuant to Rule 416(a), an indeterminate number of additional shares to prevent dilution from share splits, share dividends or similar transactions. The filing incorporates by reference the company’s future Exchange Act reports and lists standard indemnification provisions for directors and officers under Cayman Islands law.
Lichen International Limited reported that its Board of Directors approved and adopted a new 2025 Equity Incentive Plan, effective October 30, 2025. The plan is included as Exhibit 99.1 to the company’s Form 6-K.
The filing is an administrative update that adds the full text of the equity plan for reference. The report was signed by Chief Executive Officer Ya Li on November 7, 2025.
Lichen International Limited completed a private placement of equity to raise new cash. On September 15, 2025, the company agreed to sell 15,500,000 Class A ordinary shares at $1.20 per share, for a total purchase price of $18,600,000, payable in cash.
The company received the full purchase price and issued the shares on September 19, 2025. The transaction was conducted as a private offering exempt from U.S. registration under Section 4(a)(2), Regulation D and/or Regulation S, and the related securities purchase agreement form was filed as an exhibit.
Lichen International Ltd settled accrued salary owed to its Chief Executive Officer, Ya Li, by issuing equity instead of paying cash. As of August 27, 2025, the Company owed Mr. Li RMB 2,129,544 (approximately $297,000) in unpaid salary for the period from January 2025 to June 2025. To extinguish this debt, the Company and Mr. Li entered into a debt settlement and mutual release agreement under which the Company issued 65,000 Class B ordinary shares, valued at $4.57 per share, which was approximately 102% of the average closing bid price of the Company’s Class A ordinary shares over the five trading days before the agreement date. The shares were issued on August 27, 2025 under exemptions from registration provided by Section 4(a)(2) of the Securities Act of 1933 and Regulation S.